Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.

Janna M. Journeycake

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.

Original languageEnglish (US)
Pages (from-to)444-449
Number of pages6
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Volume2012
StatePublished - 2012

Fingerprint

Thrombopoietin
Idiopathic Thrombocytopenic Purpura
Splenectomy
Thrombopoietin Receptors
Therapeutics
Immunosuppressive Agents
Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b43338921f9d402e935344a4bdf2791e,
title = "Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.",
abstract = "Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30{\%} of affected children will have a prolonged course and 5{\%}-10{\%} will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.",
author = "Journeycake, {Janna M.}",
year = "2012",
language = "English (US)",
volume = "2012",
pages = "444--449",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Childhood immune thrombocytopenia

T2 - role of rituximab, recombinant thrombopoietin, and other new therapeutics.

AU - Journeycake, Janna M.

PY - 2012

Y1 - 2012

N2 - Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.

AB - Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.

UR - http://www.scopus.com/inward/record.url?scp=84879363483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879363483&partnerID=8YFLogxK

M3 - Article

C2 - 23233617

AN - SCOPUS:84879363483

VL - 2012

SP - 444

EP - 449

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -